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Abstract 
    Evaluation of atherosclerotic plaques depends on invasive intravascular 
ultrasonography (IVUS).  Carboxy-terminal telopeptide of type I collagen (ICTP) is 
produced by matrix metalloproteinase (MMP)-dependent digestion of type I collagen.  
Because vulnerable plaques are rich in type I collagen and MMPs from macrophages, 
we examined the association between serum ICTP and coronary plaques in patients with 
coronary disease.  We recruited 46 men and 17 women without renal failure or bone 
diseases affecting serum ICTP, who underwent coronary IVUS.  Serum ICTP levels 
were higher in patients with coronary plaques containing more than 10% necrotic core 
area than in patients with less than 10% necrotic core area.  A positive correlation was 
found between serum ICTP and necrotic core area.  Only serum ICTP was positively 
correlated with necrotic core area by multivariate analysis (p<0.05).  These results 
suggest that serum ICTP can be used as a non-invasive marker of vulnerable plaques in 
atherosclerotic patients. 
(148 words) 
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Introduction 
    Acute coronary syndrome aggravates morbidity and mortality, causing an increase 
in the risk of further events despite the use of percutaneous coronary intervention [1]. 
Many previous studies have demonstrated that acute coronary occlusion develops at the 
site of a vulnerable atherosclerotic plaque with a lipid-rich necrotic core [2,3]. 
Therefore, if there is a way to screen such vulnerable plaque lesions, preventive 
measures can be implemented before the development of acute coronary syndrome. 
    Intravascular ultrasound-virtual histology (IVUS-VH) uses radiofrequency analysis 
of ultrasound backscatter signals to overcome the limitations of grayscale IVUS by 
providing a more detailed plaque morphology, and is able to provide in vivo plaque 
analysis [4].  Thus, this procedure can directly detect vulnerable plaques in patients 
who are susceptible to develop acute coronary syndrome.  However, IVUS involves 
invasive procedures with the risk of vascular complications.  
    Because atherosclerotic lesions, are rich in type I collagen, and because 
macrophages producing matrix metalloproteinases (MMPs) invade into these lesions, 
type I collagen degradation products by MMPs may be increased in these lesions. 
C-terminal telopeptide of type I collagen (ICTP) is an MMP-dependent degradation 
product of type I collagen, and serum ICTP level has been used for a marker of 
destructive bone lesions by metastatic cancers [5].  In contrast to the other bone 
resorption markers such as type I cross-linked C-telopeptide (CTX) and type I 
cross-linked N-telopeptide (NTX), ICTP is not produced by cathepsin K cleavage and is 
not elevated by osteoclastic bone resorption [6].  Thus, the present study was 
undertaken to examine whether serum ICTP level can be used as a non-invasive 
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predictive marker for vulnerable atherosclerotic plaques. 
 
Patients and Methods 
    We recruited 46 men and 17 women (50 to 87 years, mean age 67.6) who were 
admitted to Takamatsu City Hospital and Tokushima University Hospital due to 
coronary symptoms, and underwent coronary angiography with IVUS from September 
2005 to September 2007.  The study was approved by institutional review board of the 
University of Tokushima Hospital.  Written informed consent was obtained from all 
the patients who presented with acute coronary syndrome before patients underwent 
diagnostic coronary angiography.  Among those patients, we randomly recruited only 
those who had at least one coronary plaque with 50 to 75% stenosis to this prospective 
study.  IVUS-VH of the coronary plaque was performed at the most severe stenosis in 
each patient.  Patients with renal dysfunction, metabolic bone diseases or thyroid 
diseases that affect serum ICTP levels were excluded.  All patients were evaluated for 
coronary risk factors including dyslipidemia, sex, current smoking, diabetes mellitus or 
hypertension.  Blood samples were taken before undergoing IVUS study after 
overnight fasting, and parameters of coronary risk factors or surrogate marker of 
vulnerable plaques were evaluated, including HbA1c (NGSP), triglyceride (TG), low 
density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, 
lipoprotein(a) (Lp(a)), high sensitivity C-reactive protein (hs-CRP) and ICTP.  Serum 
ICTP was measured by a two-antibody Telopeptide ICTP radioimmunoassay kit (Orion 
Diagnostica, Espoo, Finland). The normal range of serum ICTP was 1.8 to 5.0 ng/ml [7].  
As bone turnover markers, serum NTX and bone-specific alkaline phosphatase (BSAP) 
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were measured in comparison with ICTP. Data were expressed as means +/- SD. 
Statistical significance was determined using paired Student's t-test and analyses were 
performed by SPSS statistics 17.0 for Macintosh. A p value of less than 0.05 was 
considered to be statistically significant. 
    IVUS-VH displays the reconstructed color-coded tissue map of plaque 
composition superimposed on cross-sectional images of the coronary artery (Volcano 
Therapeutics, Inc., Rancho Cordova, California). After baseline angiography, a 3.2-F, 
30-MHz Ultrasound Imaging catheter (Boston Scientific Scimed Inc., Maple Grove, 
Minnesota) was placed distal to the target lesion. The catheter tip was subsequently 
pulled back using a motorized pullback system (Volcano Therapeutics, Inc.).  Using 
this technology, coronary artery plaques at the section of most severe luminal 
obstruction were divided into fibrotic tissue, fibro-fatty tissue, necrotic core and dense 
calcium.  Necrotic core area is composed of a mixture of lipid-like dead cells, foam 
cells and trapped blood cells. In this area, most of any real structure is lost, with some 
areas containing microcalcification as a byproduct from the dead cells, and friable areas 
next to sharp calcification become sites of gross instability and rupture [4].  Because a 
vulnerable plaque is reported to have more than 10% necrotic core without evidence of 
a fibrous cap [8], we selected the 10% area of necrotic cores as a cut-off to define 
vulnerable plaques. 
 
Results  
    Necrotic core area was 0 to 38% of the sections of the most severe stenosis in each 
patient (mean 16.1+- 8.9%).  There were 40 patients with more than 10% necrotic core 
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area in coronary plaque, and the remaining 23 patients showed less than 10% necrotic 
core area.  Fibrotic tissue occupied 60.6+-13.2%, fibrofatty tissue 14.5+-11.4%, and 
dense calcium 8.9+-9.6% of the total section area.  Figure 1 shows IVUS-VH images 
of coronary lesions with more than 10% necrotic core (A) or without vulnerable plaque 
(B). 
    We divided patients into those with 10% or more necrotic core and with less than 
10% necrotic core.  There was no significant difference between the two groups in age, 
current smoking, hypertension, diabetes mellitus, dyslipidemia, HbA1c, TG, LDL-C, 
HDL-C, Lp(a) and hs-CRP. Among bone turnover markers, only serum ICTP was 
significantly higher in the group with 10% or more necrotic core (Supplementary Table).  
Serum ICTP levels of age-matched control subjects (n=63) without atherosclerotic 
lesions by carotid ultrasonography were significantly lower (3.17 +/- 1.20 ng/ml) than 
those of the patients in this study (7.22 +/- 10.10 ng/ml) (p<0.005).  Serum ICTP 
showed no significant relationship with either BSAP (p=0.147) or NTX (p=0.228).  
    There was a significant positive correlation between serum ICTP and necrotic core 
area by regression analysis before and after logarithmic transformation (Figure 1C, 1D), 
while no significant correlation was found between hs-CRP and necrotic core area 
(p=0.241).  Furthermore, multivariate analysis after logarithmic transformation 
revealed that only ICTP was independently and positively correlated with necrotic core 
area (Table 1).  These results demonstrate that serum ICTP can be a serum surrogate 
marker for the presence of vulnerable atherosclerotic plaque lesions. 
 
Discussion 
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    Coronary vulnerable plaques cause acute coronary syndrome, including unstable 
angina and acute myocardial infarction. However, characterization and evaluation of 
coronary plaques depends on invasive examinations such as IVUS and fiberscope.  
Atherosclerotic lesions are rich in type I collagen and macrophages producing MMPs 
[9,10], and the level of serum MMPs is significantly higher in patients with ruptured 
plaque [11].  Histological examination demonstrated that activated MMPs are 
overexpressed at the atherosclerotic plaques, and suggested that the focal expression of 
activated MMPs may promote destabilization and complication of atherosclerotic 
plaque [12].  Destabilization of vulnerable plaques by angiotensin II is mediated by 
angiotensin II-induced increase in the expression and activation of MMP8 and MMP13, 
with increased type I collagen breakdown [13].  ICTP is an MMP-dependent 
degradation product of type I collagen, while other type I collagen degradation products 
used as osteoclastic bone resorption markers are formed by cathepsin K-dependent 
degradation.  In the present study, there was a significant correlation between serum 
ICTP and necrotic core area, and only serum ICTP, but not other bone turnover markers, 
was significantly correlated with the necrotic core area.  Although metastatic bone 
lesions of cancer causes an increase in serum ICTP by increased MMPs-dependent type 
I collagen degradation in the bone, none of the participants showed cancer metastasis to 
the bone.  Thus, it is likely that the source of serum ICTP in these patients is not from 
bone but from atherosclerotic plaques.  In fact, only serum ICTP showed a significant 
correlation with the necrotic core area of coronary artery directly evaluated by 
IVUS-VH.  Thus, serum ICTP can be used as a non-invasive surrogate marker for the 
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presence and severity of vulnerable plaques in patients without cancer metastasis to 
bone.  
    High sensitivity CRP has been widely used as a marker of vulnerable plaques [14], 
but can be affected by various factors including inflammation.  In the present study, 
there was a wide variation in serum hs-CRP, and no significant correlation was found 
between hs-CRP and necrotic core area.  Serum BSAP was reported to show a 
correlation with vascular stiffness [15].  However, the relationship between serum 
BSAP and atherosclerotic plaques is unclear, and no significant correlation was 
observed between serum BSAP and necrotic core area.  
    Our study has limitations. First, this is a cross-sectional study with relatively small 
sample size, and longitudinal data on serum ICTP and necrotic core area before and 
after medical interventions were not obtained.  Second, we could assess only the 
section with most severe coronary plaque in each patient.  ICTP can be released not 
only from severe coronary plaques but also from vulnerable plaques in other areas.  
Further studies will be necessary to delineate patients and conditions in which serum 
ICTP can be used as a surrogate marker for the development of acute coronary 
syndrome. 
    In conclusion, serum ICTP is correlated with necrotic core area of coronary plaque 
lesions in patients with coronary heart disease, and can be used as a non-invasive 
surrogate marker for vulnerable plaque lesions in atherosclerotic patients. 
(1,491 words) 
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Table 1. Multivariate analysis of the correlation of various risk factors with necrotic 
core area. 
 
Coeffeicient SE  T value     95%CI      p value 
Sex  -4.68       2.96   1.578   -10.629 - 1.277   0.120 
Age   0.01       0.10   0.059    -0.201 - 0.213   0.952 
Diabetes mellitus  -0.18       2.33   0.076    -4.861 - 4.505   0.939 
Hypertension      -2.80    2.48   1.129    -7.793 - 2.184   0.263 
 
 
Dyslipidemia      -3.55      2.42   1.464    -8.418 – 1.321   0.148 
Serum TG         0.00      0.02   0.059    -0.043 - 0.046   0.952 
Serum LDL-C     -0.03      0.04   0.936    -0.108 - 0.039   0.351 
Serum HDL-C     -0.03      0.08   0.396    -0.197 - 0.132   0.693 
Serm Lp(a)        0.35      1.22   0.288    -2.104 – 2.808   0.775 
Serum ICTP       4.40      1.71   2.569     0.969 – 7.839   0.012 
 
TG; triglyceride, LDL-C; low-density lipoprotein cholesterol, HDL-C; high-density 
lipoprotein cholesterol, Lp(a); lipoprotein (a), ICTP; C-terminal telopeptide of type I 
collagen 
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Figure legends 
Figure 1. Images of atherosclerotic coronary lesions using intravascular 
ultrasound-virtual histology (IVUS-VH), and the relationship between serum ICTP and 
necrotic core area.   
Green area represents fibrous tissue, yellow area fibro-fatty plaque, red area necrotic 
core, and white area represents dense calcium.  (A) An IVUS-VH section of atheroma 
lesion with 25% necrotic core area, representing unstable atheromatous lesion. (B) A 
section of atheroma lesion with 4% necrotic core, representing stable atheromatous 
lesion. (C) Regression analysis of the relationship between serum ICTP and necrotic 
core area (%).  Positive correlation was observed between serum ICTP and necrotic 
core area (p<0.03).  (D) Regression analysis of relationship between logarithmic 
transformed serum ICTP and necrotic core area (p<0.02).  
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Supplementaly Table. Comparison of clinical characteristics between patients with 10% 
or more and less than 10% necrotic core for atherosclerotic risk factors and bone turnover 
markers.   
 
NC(%)                      < 10                 10?                total                p-value 
N                             (23)                   (40)                 (63) 
Age                      64.3+-9.9         69.5+-10.4      67.6+-10.4 
Current smoking       4                     2                    6 
Hypertension            18                   25                  43 
Diabetes mellitus     14                   19                  33 
Dyslipidemia            17                   17                  34 
HbA1c(%)                6.2+-1.4         6.2+-1.3         6.2+-1.4               0.995          
TG(mg/dL)          128.7+-57.2   116.9+-56.0    120.8+-56.2            0.504 
LDL-C(mg/dL)    128.2+-39.5   117.0+-26.4    123.2+-30.7            0.222 
HDL-C(mg/dL)     47.1+-15.1     45.9+-14.8      46.1+-15.0            0.694 
Lp(a) (mg/dL)       19.0+-16.7     29.2+-27.8      25.0+-24.7            0.172 
Hs-CRP(mg/dL) 0.123+-0.169  0.439+-0.981  0.340+-0.820          0.241 
BSAP(U/mL)        19.9+-5.9        23.5+-9.3        21.9+-8.2             0.147 
NTX(nmolBCE/L) 13.2+-6.8       14.5+-5.4        14.4+-6.1             0.220 
ICTP(ng/mL)         4.29+-1.12     8.96+-4.81      7.22+-10.10        <0.04 
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NC; necrotic core, TG; triglyceride, LDL-C; low-density lipoprotein cholesterol, 
HDL-C; high-density lipoprotein cholesterol, Lp(a); lipoprotein (a), Hs-CRP; high 
sensitivity C-reactive protein, BSAP; bone-specific alkaline phosphatase, NTX; type I 
cross-linked N-telopeptide, ICTP; C-terminal telopeptide of type I collagen 
 
